Arabic Arabic English English French French German German
dark

Drug combination shows meaningful responses for malignant peritoneal mesothelioma patients

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen. Responses occurred in patients regardless of PD-L1 expression status and tumor mutation burden. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Study shows cannabis terpenes provide pain relief, contribute to ‘entourage effect’

Next Post

Personalized 3D-printed knee implant could help thousands of arthritis sufferers

Related Posts
Total
0
Share